Chenfei Chi

687 total citations
26 papers, 489 citations indexed

About

Chenfei Chi is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Chenfei Chi has authored 26 papers receiving a total of 489 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 8 papers in Molecular Biology. Recurrent topics in Chenfei Chi's work include Prostate Cancer Treatment and Research (19 papers), Radiopharmaceutical Chemistry and Applications (7 papers) and Prostate Cancer Diagnosis and Treatment (6 papers). Chenfei Chi is often cited by papers focused on Prostate Cancer Treatment and Research (19 papers), Radiopharmaceutical Chemistry and Applications (7 papers) and Prostate Cancer Diagnosis and Treatment (6 papers). Chenfei Chi collaborates with scholars based in China, France and United States. Chenfei Chi's co-authors include Wei Xue, Jiahua Pan, Yinjie Zhu, Jianjun Sha, Liancheng Fan, Baijun Dong, Baijun Dong, Yong Huang, Xiaoguang Shao and Lixin Zhou and has published in prestigious journals such as The Journal of Urology, Frontiers in Microbiology and Journal of Cellular Physiology.

In The Last Decade

Chenfei Chi

26 papers receiving 481 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Chenfei Chi China 14 287 177 168 168 65 26 489
V. Papadimitrakopoulou United States 13 304 1.1× 313 1.8× 223 1.3× 110 0.7× 47 0.7× 41 606
Curtis Dunshee United States 11 424 1.5× 225 1.3× 107 0.6× 130 0.8× 110 1.7× 41 548
Tianli Zhang China 14 274 1.0× 294 1.7× 236 1.4× 106 0.6× 30 0.5× 24 638
Li‐Yan Khor United States 13 339 1.2× 173 1.0× 244 1.5× 143 0.9× 52 0.8× 13 532
Davide Bosso Italy 12 167 0.6× 132 0.7× 133 0.8× 70 0.4× 57 0.9× 18 366
Letizia Laera Italy 12 179 0.6× 119 0.7× 101 0.6× 72 0.4× 51 0.8× 32 329
Carmelo Lupo Italy 11 137 0.5× 176 1.0× 150 0.9× 83 0.5× 32 0.5× 25 390
Angel Qin United States 12 201 0.7× 343 1.9× 178 1.1× 122 0.7× 25 0.4× 33 561
Peter W. Nagle Netherlands 11 88 0.3× 174 1.0× 140 0.8× 75 0.4× 101 1.6× 16 450
Prabhakar Pandey United States 11 299 1.0× 156 0.9× 200 1.2× 174 1.0× 31 0.5× 15 584

Countries citing papers authored by Chenfei Chi

Since Specialization
Citations

This map shows the geographic impact of Chenfei Chi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chenfei Chi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chenfei Chi more than expected).

Fields of papers citing papers by Chenfei Chi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chenfei Chi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chenfei Chi. The network helps show where Chenfei Chi may publish in the future.

Co-authorship network of co-authors of Chenfei Chi

This figure shows the co-authorship network connecting the top 25 collaborators of Chenfei Chi. A scholar is included among the top collaborators of Chenfei Chi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chenfei Chi. Chenfei Chi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chi, Chenfei, Xiaowei Ma, Xiangguo Lv, et al.. (2024). Towards Automatic Evaluation for LLMs' Clinical Capabilities: Metric, Data, and Algorithm. 5466–5475. 4 indexed citations
2.
3.
Zhu, Yinjie, Liancheng Fan, Yiming Gong, et al.. (2023). Transcriptomic signature defines two subtypes of locally advanced PCa with distinct neoadjuvant therapy benefits. Frontiers in Oncology. 13. 963411–963411. 1 indexed citations
4.
Chi, Chenfei, Jiazhou Liu, Liancheng Fan, et al.. (2022). Efficacy of neoadjuvant docetaxel + cisplatin chemo-hormonal therapy versus docetaxel chemo-hormonal therapy in patients with locally advanced prostate cancer with germline DNA damage repair gene alterations. Therapeutic Advances in Medical Oncology. 14. 4287540388–4287540388. 6 indexed citations
5.
Chi, Chenfei, Liancheng Fan, Baijun Dong, et al.. (2021). Efficacy of Neoadjuvant Chemohormonal Therapy in Oligometastatic Hormone-Sensitive Prostate Cancer: A Prospective, Three-Arm, Comparative Propensity Score Match Analysis. Clinical Genitourinary Cancer. 19(4). e223–e234. 7 indexed citations
6.
Dong, Baijun, Liancheng Fan, Bin Yang, et al.. (2021). Use of Circulating Tumor DNA for the Clinical Management of Metastatic Castration-Resistant Prostate Cancer: A Multicenter, Real-World Study. Journal of the National Comprehensive Cancer Network. 19(8). 905–914. 30 indexed citations
7.
Han, Qing, Chenfei Chi, Yinjie Zhu, et al.. (2020). Transcriptional regulation of PRKAR2B by miR-200b-3p/200c-3p and XBP1 in human prostate cancer. Biomedicine & Pharmacotherapy. 124. 109863–109863. 25 indexed citations
8.
Fan, Liancheng, Yinjie Zhu, Jiahua Pan, et al.. (2020). Comparative Analysis of Genomic Alterations across Castration Sensitive and Castration Resistant Prostate Cancer via Circulating Tumor DNA Sequencing. The Journal of Urology. 205(2). 461–469. 33 indexed citations
9.
Xia, Lei, Jian Sun, Shaowei Xie, et al.. (2020). PRKAR2B‐HIF‐1α loop promotes aerobic glycolysis and tumour growth in prostate cancer. Cell Proliferation. 53(11). e12918–e12918. 45 indexed citations
10.
Ma, Xiaowei, Chenfei Chi, Liancheng Fan, et al.. (2019). The Microbiome of Prostate Fluid Is Associated With Prostate Cancer. Frontiers in Microbiology. 10. 1664–1664. 32 indexed citations
11.
Pan, Jiahua, Chenfei Chi, Yinjie Zhu, et al.. (2019). Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: A retrospective comparative study. Urologic Oncology Seminars and Original Investigations. 37(12). 991–998. 31 indexed citations
12.
Sha, Jianjun, Qing Han, Chenfei Chi, et al.. (2019). Upregulated KDM4B promotes prostate cancer cell proliferation by activating autophagy. Journal of Cellular Physiology. 235(3). 2129–2138. 35 indexed citations
13.
Fan, Liancheng, Baijun Dong, Chenfei Chi, et al.. (2018). Serum levels of neuroendocrine differentiation markers predict the prognosis of patients with metastatic castration resistant prostate cancer treated with abiraterone acetate. Zhonghua miniao waike zazhi. 39(5). 362–366. 1 indexed citations
14.
15.
16.
17.
Fan, Liancheng, Xiao Wang, Chenfei Chi, et al.. (2017). Prognostic nutritional index predicts initial response to treatment and prognosis in metastatic castration‐resistant prostate cancer patients treated with abiraterone. The Prostate. 77(12). 1233–1241. 35 indexed citations
18.
Fan, Liancheng, Chenfei Chi, Wen Cai, et al.. (2017). Serum Pre-Albumin Predicts the Clinical Outcome in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Abiraterone. Journal of Cancer. 8(17). 3448–3455. 16 indexed citations
19.
Fan, Liancheng, Yanqing Wang, Chenfei Chi, et al.. (2017). Chromogranin A and neurone‐specific enolase variations during the first 3 months of abiraterone therapy predict outcomes in patients with metastatic castration‐resistant prostate cancer. British Journal of Urology. 120(2). 226–232. 24 indexed citations
20.
Dong, Baijun, Liancheng Fan, Yanqing Wang, et al.. (2017). Influence of abiraterone acetate on neuroendocrine differentiation in chemotherapy‐naive metastatic castration‐resistant prostate cancer. The Prostate. 77(13). 1373–1380. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by V. Papadimitrakopoulou Breakdown of academic impact, for papers by Curtis Dunshee Breakdown of academic impact, for papers by Tianli Zhang Breakdown of academic impact, for papers by Li‐Yan Khor Breakdown of academic impact, for papers by Davide Bosso Breakdown of academic impact, for papers by Letizia Laera Breakdown of academic impact, for papers by Carmelo Lupo Breakdown of academic impact, for papers by Angel Qin Breakdown of academic impact, for papers by Peter W. Nagle Breakdown of academic impact, for papers by Prabhakar Pandey
Rankless by CCL
2026